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Abstract. Ovarian cancer is complex disease composed of different histological grades and types. However, the underlying
molecular mechanisms involved in the development of different phenotypes remain largely unknown. Epidemiological studies
identiﬁedmultipleexogenous andendogenous riskfactorsforovariancancerdevelopment. Amongthem,aninﬂammatorystromal
microenvironment seems to play a critical role in the initiation of the disease. The interaction between such a microenvironment,
genetic polymorphisms, and different epithelial components such as endosalpingiosis, endometriosis, and ovarian inclusion cyst
in the ovarian cortex may induce different genetic changes identiﬁed in the epithelial component of different histological types
of ovarian tumors. Genetic studies on different histological grades and types provide insight into the pathogenetic pathways for
the development of different disease phenotypes. However, the link between all these genetic changes and the etiological factors
remains to be established.
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1. Introduction
OvariancancerkillsmoreAmericanwomenthanany
othergynecologiccancerandis,forthesamegroup,the
ﬁfth most common cause of cancer-related death [1].
Although all human ovary cells, including epithelial,
stromal, and germ cells, may undergoneoplastic trans-
formation, 80% to 90% of malignant ovarian tumors
come from the single layer of epithelial cells covering
∗Corresponding author: Samuel C. Mok, Laboratory of Gyne-
cologic Oncology, Brigham and Women’s Hospital, BLI-447, 221
Longwood Avenue, Boston, MA 02115, USA. Tel.: +1 617 278
1096; Fax: +1 617 9750818; E-mail: scmok@rics.bwh.harvard.edu.
the ovaries [2]. The human ovarian surface epithelium
(HOSE) is believed to originate from the mesothelium
of the embryonic gonad (the mullerian epithelium). In
contrast to colorectal cancer, ovarian cancer does not
have well-deﬁned precursor lesions. It has more com-
plex histological features and early stage cancer sam-
plesaremoredifﬁculttoobtain. Thesedifferenceslim-
it our ability to identify risk factors, which are impor-
tant for the pathogenesis of ovarian cancer. In the last
decade, multiple endogenous and exogenous risk fac-
tors as well as genetic alterations have been identiﬁed
for ovarian cancer. In this review, we will summarize
some of these risk factors and genetic changes identi-
ﬁed forall or speciﬁc histological types ofovariancan-
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cer, which may provide insights into the development
of the disease.
2. Histology
Epithelial ovarian tumors are classiﬁed as benign,
low malignant potential (borderline), or malignant ac-
cording to the World Health Organization (WHO) cri-
teria [3]. Benign epithelium is characterized by a sin-
gle or minimally stratiﬁed layer of cells. These cells
are columnar and often ciliated in serous tumors and
contain abundant apical cytoplasmic mucin in muci-
nous tumors. Atypical epithelium lining of borderline
or low malignant potential (LMP) tumor is character-
ized by cellular proliferation and pleomorphism with-
out stromal invasion. Malignant epithelium demon-
strates marked atypia, increased mitotic activity, and
stromal invasion. Although the histopathologic fea-
tures of ovarian tumors vary substantially, all tumors
exhibit characteristics similar to those of the mullerian
epithelium [4]. There are four major histological types
ofovariancancer. Seroustumorsarethe mostcommon
form of ovarian neoplasm with epithelial cells resem-
bling those of the fallopian tube. They comprise about
50–60% of primary epithelial ovarian tumors. Muci-
nous tumors are cystic tumors with locules lined with
mucin-secretingepithelialcellsresemblingeitherendo-
cervical or colonic epithelium. They comprise approx-
imately 8–10% of primary epithelial ovarian tumors.
Endometrioid tumors are tumors with epithelial cells
resemblingendometrialglandsoftheendometriumand
together with Clear cell lesions constitute about 10%
of epithelial tumors. Other tumor cell types include
Brenner, mixed epithelial type and undifferentiated.
3. Epidemiology
Althoughthe etiologyofovariancanceris unknown,
scientists have proposed several hypotheses to explain
theepidemiologicfactorscorrelatingwithitsincidence.
Factors that have been associated with a lower risk of
ovarian cancer include having had one or more full-
termpregnancies,havingusedoralcontraceptives,hav-
ing breast-fed, and having undergone a tubal ligation
or hysterectomy [5]. All these events would tend to
reduce the number of ovulations a woman has during
her lifetime. And although early menarche – which
mayresultinmoreovulations–hasnotbeenassociated
with an increased incidence of ovarian cancer, studies
haveshownanincreasedincidenceofovariancancerin
women who are nulliparous, have had fewer pregnan-
cies, have never breast-fed, or are infertileother condi-
tions that may increase the number of ovulations in a
woman’s lifetime [4,6–8].
Theapparentoverallrelationshipbetweenovulations
history and risk has prompted the development of sev-
eraluniﬁedhypothesesof ovariancancerpathogenesis.
3.1. Hypothesis 1
In the earliest of these, it was postulated that “inces-
sant ovulation” leads to neoplastic transformation of
HOSE cells [9,10]. This hypothesis states that every
ovulation creates a wound that HOSE cells repair by
undergoingpostovulationmitosis andproliferationand
that the increase in cell proliferationincreases the like-
lihood that age- or toxin-caused aberrations in DNA
repair mechanisms will permit genetic damage to go
unrepaired and become potentially carcinogenic muta-
tions[11–14]. Severalstudieshavefoundevidencethat
supportstheincessantovulationhypothesis. Inone,the
repeated subculture of rat ovarian surface epithelium
(OSE) cells induced spontaneous cellular transforma-
tion and chromosomal aberrations [15,16]. In anoth-
er study, sheep OSE cells examined from the site of
stigma formation showed evidence of oxidative DNA
damage, p53 expression, and apoptosis [17].
3.2. Hypothesis 2
Another hypothesis explaining the relationship be-
tween ovulation history and ovarian cancer risk in-
volves the exposure of HOSE cells to the ovarian stro-
ma [18,19] (Fig. 1). Normally, the OSE is separated
from the stroma by a basement membrane and a layer
of thin connective tissue [11]. The formation of an in-
clusion cyst breaks down that barrierand brings HOSE
cellsintothehormonalmilieuofthestroma,prompting
neoplastic growth [20].
3.3. Hypothesis 3
Thefact thattheincidenceofovariancancerincreas-
es dramatically in women above the age of 45 years
and peaks between 10 and 20 years after menopause
has led tothe development of a “gonadotropin stimu-
lation” hypothesis, in which the elevated gonadotropin
levels found in menopausal and postmenopausalwom-
en are a causative factor in ovarian cancer [20]. Sup-
port this hypothesis are results from several case stud-S.C. Mok et al. / Etiology and pathogenesis of epithelial ovarian cancer 369
Fig. 1. Ovarian microenvironment and the initiation of an epithelial ovarian tumor. We hypothesize that microenvironment in the cortex of the
ovary, which has been subjected to chronic inﬂammation due to either incessant ovulation and/or infection induces dysplatic changes in epithelial
cells (including ovarian surface epithelial stem cells) lining the mullerian inclusion cyst. Immune cells inﬁltration, activated ﬁbroblast formation,
and microvessels proliferation combined with other factors in the microenvironment induce dysplastic and subsequently malignant transformation
of the normal ovarian surface epithelia (HOSE) stem cell to a cancer stem cell, which gives rise to heterogenous daughter cells through clonal
expansion and differentiation.
ies in which women developed ovarian cancer short-
ly after ovulation had been induced with clomiphene
citrate, a gonadotropinformulation, or another fertility
drug [21–23]. However, more recent studies have sug-
gested that gonadotropinshave a protective rather than
inductive role in ovarian carcinogenesis. In one study,
theserumlevelsofgonadotropins,particularlyfollicle-
stimulating hormone, were lower in ovarian cancer pa-
tients who were postmenopausal than in patients who
were premenopausal [24]. In another study, a group
of 25- to 49-year-old women with ovarian cancer had
lower luteinizing hormonelevels than their cancer-free
peers [25].
3.4. Hypothesis 4
Like the gonadotropin stimulation hypothesis, epi-
demiologic observations made in the past decade sug-
gest several other classes of hormones contribute to
ovarian cancer pathogenesis, including androgens, es-
trogens, progesterone, and insulin-like growth factor-
I [26–28].
Most of these hypotheses have been focusing on the
effectofriskfactorsonOES cells. However,theremay
be a speciﬁc group of cells that are more susceptible
to malignant transformation. Based on recent cancer
stemcellstudies,ithasbeenhypothesizedthatdifferent
histologic types of epithelial ovarian cancer are initiat-
ed by the malignant transformation of a corresponding
progenitor or stem cell in the OSE. (Fig. 1) [29,30].
Uninterruptedcyclesofovulationandepithelialreplen-
ishmentfrommitoticstemcellsincreasetheriskforde-
velopmentofovariancancerinnulliparouswomen[29,
30].
4. Endogenous risk factors
Combination of endogenous risk factors such as
ovarianmicroenvironmentand genetic polymorphisms
may be acting on the epithelial progenitor cells in the
OSE or mullerian epithelium of inclusion cysts, and
those cells may have the potential to differentiate into
different histologic types of ovarian tumors. In addi-370 S.C. Mok et al. / Etiology and pathogenesis of epithelial ovarian cancer
tion, these factors may also act on other epithelial cell
types, such as endometrial cells, which some studies
have implicated as cells of origin in epithelial ovarian
tumors [31].
4.1. Inﬂammatory ovarian microenvironment
Inﬂammation has been suggested to be a major fac-
tor leading to epithelial ovarian cancer. For example,
epidemiologic data have shown that asbestos and talc
exposure increased ovarian cancer risk [32]. Studies
have also foundthat endometriosis [33], pelvic inﬂam-
matory disease [34], and mumps viral infection [35]
are positively associate with ovarian cancer risk. In
contrast, tubal ligations and hysterectomies, which are
thought to reduce the exposure of the OSE to envi-
ronmental inﬂammation initiators have been shown to
reduce the risk of ovarian cancer [33,36,37]. It has
been noted that the ovulatory process itself resembles
an inﬂammatory reaction, with leukocytic inﬁltration,
the release of nitric oxide and inﬂammatory cytokines,
vasodilatation,DNArepair,andtissueremodeling[38–
42]. As epidemiological studies suggest that “inces-
sant ovulation" may lead to neoplastic transformation
of HOSE cells [9,10] as described in previous section,
the inﬂammatory responses the ovulation cycle causes
may contribute to the development of ovarian cancer.
Several inﬂammatory factors, such as cytokines se-
creted by the inﬁltrating leukocytes have been impli-
cated in ovarian carcinogenesis. Some studies sug-
gest that pro-inﬂammatorycytokines play a major role
in ovarian cancer pathogenesis because both ovari-
an tumors and normal tissue have been reported to
have an abundance of these cytokines [43–45]. Tu-
mor necrosis factor alpha (TNF-α) is one of the key
pro-inﬂammatory cytokines in ovarian function. One
study showed that TNF-α was localized to the the-
cal endothelial cells of pre-ovulatory follicles, and its
levels within the follicular apex declined abruptly as
ovulation approached, whereas the level in cells with-
in the counterpart basal wall was unaffected. TNF-α
was secreted, within a limited diffusionradius, into the
progenitor site of rupture [46]. Another study showed
TNF-α was activated by plasmin in endothelial cells
withintheovary˜ cite47. Itwas suggestedthat thebioac-
tive, soluble form of TNF-α generated from the en-
dothelial cells of pre-ovulatory follicles may have an
important role in the biomechanics of apical follicu-
lar weakening and ovarian rupture [46]. TNF-α was
shown to contribute to basement membrane degrada-
tion during ovulation [48]. TNF-α was found to in-
creasetheactivityofmatrixmetalloproteinase(MMP)-
9 and urokinase-type plasminogen activator secreted
from HOSE cells, causing degradation and structural
reorganizationof the basement membranecomponents
(collagen IV and laminin). This study implicates the
potential roles of TNF-a, uPA, and MMP-9 in ovarian
surfaceepithelialbasementmembranedegradationand
remodeling, which are processes during ovulation and
maycontributetoepithelialtransformation. Italsomay
provide a molecular mechanism linking ovulation and
ovarian cancer risk.
Besides the leukocytes, stromal ﬁbroblasts in the in-
ﬂammatory ovarian microenvironment may also sup-
port the development of tumors [49]. One of the
molecules that is induced markedly by inﬂammation
related growth factors and cytokines in the stromal ﬁ-
broblast is tenascin-C [50–54]. Tenascin-C has been
shown to be up-regulated in mammalian tissue of a
MMP3 breast carcinogenesis model several weeks be-
fore signs of premalignant lesions were observed sug-
gesting that tenascin-C plays an early role in tumorige-
nesis [55]. In addition, we have recently demonstrated
that ovarian stromal ﬁbroblast treated with TNF-α in-
duced MMP-3 expression (personal communication).
Since a recent study showed that mouse mammary ep-
ithelial cells exposed to MMP-3 induced the expres-
sion of an alternatively spliced form of Rac1, which
caused an increase in cellular reactive oxygen species
(ROS), and the ROS stimulated the expression of the
transcription factor Snail and epithelial-mesenchymal
transition(EMT),andcausedoxidativedamagetoDNA
and genomic instability [56], we hypothesize that up-
regulation of MMP-3 in an inﬂammatory stromal mi-
croenvironment may lead to malignant transformation
of HOSE cells.
4.2. Genetic factor
In addition to risk factors that affect the ovarian mi-
croenvironment,other intrinsic factors, such as genetic
polymorphisms,may play a role in the pathogenesis of
different histologic types of ovarian cancer. For exam-
ple,high-penetrancegenessuchas breastcancer1,ear-
ly onset (BRCA1) has been shown to increase the risk
of epithelial ovarian cancer, particularly serous carci-
noma [57]. Low-penetrance susceptibility genes have
been shown to inﬂuence the risk of different histologic
typesofepithelialovariancancer. Forexample,theglu-
tathione S-transferase M1 (GSTM1) null genotype has
been associated with an increased risk of endometri-
oid or clear cell invasive cancer [58,59]. In addition,S.C. Mok et al. / Etiology and pathogenesis of epithelial ovarian cancer 371
while possession of the A2 variant of P450c17alpha
gene (CYP17) appeared to increase risk for all types
of ovarian cancer, possession of the Val/Met variant of
catechol-O-methyltransferase (COMT) decreased the
risk for mucinous tumors [60]. These ﬁndings must be
veriﬁed by independent studies with large case-control
populations to further conﬁrm the association between
a particular polymorphismwith ovarian cancer risk. In
addition, further exploration of potential pathogenet-
ic mechanisms is necessary. Using the newly devel-
oped high-throughputsingle nucleotide polymorphism
genotyping platform [61] combined with a large pop-
ulation of case and control specimens, we should have
the opportunity to identify genetic risk factors for the
development of different histologic types of ovarian
tumors.
5. Pathogenetic pathways for different histologic
types of ovarian cancer
5.1. Morphologic evidence
While it is believed that the ovarian microenviron-
ment plays a major role in the etiology of ovarian
cancer, the pathogenetic pathways involved in the de-
velopment of different histologic types of epithelial
ovarian tumors remain largely unknown. The precur-
sors of even the most common histologic types of ep-
ithelial ovarian cancer – serous and mucinous – have
not yet been identiﬁed. However, several uncom-
mon histopathologic features that have been identiﬁed
in early-stage ovarian tumors may give insight into
the pathogenesis of epithelial ovarian tumors (Fig. 2).
First,bothlow-andhigh-grademucinousovariancarci-
nomas are frequently found to have coexisting benign,
borderline,andinvasiveepithelialcomponents[62,63].
In contrast, only a small percentage of low-grade or
high-gradeserous ovariancarcinomas contain all these
types of components[63]. These data suggest that mu-
cinous carcinomas but not serous carcinomas may de-
velop from the benign or borderline lesions. Second,
incidental microscopic serous carcinomas, which are
high-grade carcinomas, have been identiﬁed in grossly
normal ovaries [64]. This is further support the no-
tionthathigh-gradeserouscarcinomasdevelopdenovo
and do not develop from benign or borderline lesions.
Third, endosalpingiosis – which consists of one lay-
er of well-demarcated columnar-to-cuboidal cells in-
cluding ciliated cells – is frequently seen in the ovary
and has been associated with serous cystadenocarcino-
ma suggesting that endosalpingiosis may represent the
precursor for serous tumors [65–67].
5.2. Molecular evidence
Based on the above histopathologic ﬁndings and
the prevalence of each histologic subtype of epithe-
lial ovarian cancer, we developed a hypothesis to ex-
plain serous and mucinous ovarian tumor development
(Fig. 2). This hypothesis states that most ovarian tu-
morsdevelopfromovarianinclusioncystsarisingfrom
the OSE. In most cases of serous cancer, the major-
ity of serous BOTs develop directly from ovarian in-
clusion cysts, without the cystadenoma stage. Alter-
natively, the epithelial lining of the cyst develops into
a mucinous or serous cystadenoma by following one
of two distinct pathogenetic pathways, as follows. A
mucinous cystadenoma would give rise to a mucinous
borderlineovariantumor(BOT),asubsetofwhichmay
progress,givingrise to invasivelow- andperhapshigh-
grade grade mucinous carcinomas. A serous cystade-
nomawouldgiverise to a serousBOT, in whichbenign
and borderlinefeatures are rare, in contrast to their fre-
quent presence in mucinous BOTs. Our recent expres-
sion proﬁling analysis of serous BOTs and serous low-
andhigh-gradecarcinomassuggestedthatserousBOTs
and low-grade carcinomas may represent developmen-
tal stages along a continuum of disease development
and progression [68]. Thus, we hypothesize that a ma-
jority of high-grade serous carcinomas derive de novo
from ovarian cysts or ovarian endosalpingiosis. This
hypothesis is consistent with the two-tier system re-
cently proposedfor the gradingserous carcinomas[69,
70]. Furthermore, we propose that serous carcinomas
may also develop on the ovarian surface directly from
OSE cells. This is supported by the ﬁnding that inva-
sive serous carcinomas can be identiﬁed sitting on the
surfaceoftheovarywithoutanyovariancorticalstroma
involvement.
Studying genetic changes in different types of ovar-
ian tumors provide insight into the pathogenesis path-
ways for ovarian cancer. In a previous study, single-
strand conformation polymorphism analyses revealed
Kirsten ras oncogene homolog (KRAS) mutations in
BOTs, with mutations present in 63% of mucinous
BOTs and 75% of invasive mucinous ovarian can-
cers [71]. These data suggest that KRAS mutations are
involved in the development of mucinous BOTs and
support the notion that mucinous BOTs may represent
a phase of development along the pathologic continu-
um between benign and malignant mucinous tumors.
Both serous BOTs and serous invasive ovarian cancers
have demonstrated a lower KRAS mutation rate than
mucinoustumors,buttheKRASmutationrateinserous372 S.C. Mok et al. / Etiology and pathogenesis of epithelial ovarian cancer
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Fig. 2. Pathogenetic pathways of epithelial ovarian tumors of different histologic types. Most ovarian tumors develop from ovarian inclusion
cysts arising from the OSE. In most cases of serous cancer, the majority of serous BOTs develop directly from ovarian inclusion cysts, without
the cystadenoma stage. Alternatively, the epithelial lining of the cyst develops into a mucinous or serous cystadenoma by following one of two
distinct pathogenetic pathways, as follows. A mucinous cystadenoma would give rise to a mucinous BOT, a subset of which may progress, giving
rise to invasive low- and perhaps high-grade grade mucinous carcinomas. A serous cystadenoma or endosalpingiosis would give rise to a serous
BOT, in which benign and borderline features are rare, in contrast to their frequent presence in mucinous BOTs. Serous BOTs and low-grade
carcinomas may represent developmental stages along a continuum of disease development and progression. However, a majority of high-grade
serous carcinomas derive de novo from ovarian cysts or ovarian endosalpingiosis. Endometrioid and clear cell carcinomas may develop from
endometriosis. BOT, borderline ovarian tumor, IEOC, invasive epithelial ovarian cancer.
BOTs is signiﬁcantly higher than that in serous inva-
sive cancers. These data suggest that serous BOTs and
invasive carcinomas may have different pathogenetic
pathways, and only a small percentageof serous BOTs
may progress to invasive cancers [71].
Loss of heterozygosity (LOH) studies have been
widely used to identiﬁed minimally deleted regions
where tumor suppressor genes may reside. We previ-
ously identiﬁed such several common loss regions by
using 105 microsatellite markers to perform detailed
deletion mappingon chromosomes1, 3, 6, 7, 9, 11, 17,
and X in BOTs, invasive ovarian cancers, and serous
surfacecarcinomaof theovary. Exceptat the androgen
receptor (AR) locus on the X chromosome [72], BOTs
showed signiﬁcantly lower LOH rates (0%–18%) than
invasivetumors at all loci screened, suggestingthat the
LOH rate at autosomes is less important in the devel-
opment of BOTs than more advanced tumors. Based
on these and other results, the importance of LOH at
the AR locus in BOTs and invasive cancers remains
undetermined. However, several studies have found
differencesin LOH rates on other chromosomes. LOH
at the p73 locus on 1p36 was found in both high- and
low-grade ovarian and surface serous carcinomas, but
not in borderline ovarian tumors. In one study, LOH
rates at 3p25,6q25.1-26,and7q31.3were signiﬁcantly
higher in high-grade serous carcinomas than in low-
grade serous carcinomas, mucinous carcinomas, and
borderlinetumors [73–75]. In another study, LOH rate
at a 9-cM region on 6q23-24 were signiﬁcantly high-
er in surface serous carcinomas than in serous ovarian
tumors [76]. In addition, multiple minimally deleted
regions have been identiﬁed on chromosomes 11 and
17. LOHata4-cMregiononchromosome11p15.1and
an 11-cM region on chromosome 11p15.5 were found
only in serous invasive tumors, and the LOH rates inS.C. Mok et al. / Etiology and pathogenesis of epithelial ovarian cancer 373
11p15.1and 11p15.5were signiﬁcantly higherin high-
grade than low-grade serous tumors [77]. Similarly,
signiﬁcantly higher LOH rates were identiﬁed at the
TP53 locus on 17p13.1 and the NF1 locus on 17q11.1
in high-gradeserous carcinomas than in low-gradeand
borderlineseroustumorsandallmucinoustumors[78].
LOH at the region between THRA1 and D17S1327,in-
cluding the BRCA1 locus on 17q21, was found exclu-
sively in high-grade serous tumors [79]. In general,
the fact that LOH rates at multiple chromosomal sites
were signiﬁcantly higher in serous than in mucinous
tumor subtypes suggest that serous and mucinous tu-
mors may havedifferentpathogeneticpathways. Since
tumor suppressor genes are implicated to be located in
chromosomalregionsdemonstratingwithLOH,further
analysisingeneslocatedintheminimaldeletedregions
may provide insights into genes that may be important
for the pathogenesis of serous and mucinous ovarian
tumors.
Studying genetic changes in endometriosis, en-
dometrioid and clear cell ovarian cancer also provides
insightsintopathogeneitcpathwaysinthedevelopment
of these tumortypes. Endometriosisis highlyassociat-
ed with endometrioid and clear cell carcinomas (28%
and 49%, respectively), in contrast to its very low fre-
quency of association with serous and mucinous car-
cinomas of the ovary (3% and 4%, respectively) [80].
This fact furnishes strong evidence that endometrio-
sis is a precancerous lesion for both endometrioid and
clear cell carcinomas. Using a molecular genetic ap-
proach,Campbelletal.[81]andJiangetal.[82]detect-
ed genetic lesions common to the carcinoma and the
adjacent endometriotictissue; Obata et al. [83]showed
that endometrioid but not serous or mucinous epithe-
lial ovarian tumors had frequent PTEN/MMAC muta-
tions. In addition, the loss of PTEN immunoreactivi-
ty has been reported in a signiﬁcantly higher percent-
age of clear cell and endometrioidovariancancers than
cancers of other histologic types [84]. Dinulescu et
al. [85] recently demonstrated that the expression of
oncogenic KRAS or conditional PTEN deletion within
the OSE induces preneoplastic ovarian lesions with an
endometrioid glandular morphology. Furthermore, the
combinationofthetwomutationsintheovaryledtothe
inductionof invasiveand widely metastatic endometri-
oid ovarian adenocarcinomas. These data further sug-
gest that tumors with differenthistologicsubtypes may
arise through distinct developmental pathways.
6. Conclusions and future directions
Thepathogenesisofovariancancerisacomplexpro-
cess, which may involve the interaction of HOSE, pro-
genitor stem cells or ovarian endometriotic cells with
the stromal cells in an inﬂammatory ovarian microen-
vironment. That in turn may induce the dysplastic and
subsequentlymalignanttransformationanddifferentia-
tionofthesecellsintodifferenthistologictypesofovar-
ian cancer. Interactions between environmental and
other intrinsic risk factors, such as genetic polymor-
phisms, certainly play a role in the pathogenesisof dif-
ferent histologic types of ovarian cancer. The develop-
ment of microdissection and cell separation technolo-
gies enables investigators to dissect out each compo-
nent of the normal and tumor tissue and examine gene
expressionproﬁlesofeachcomponent. Theapplication
of newly developed three dimension (3D) culture and
animal models, and SNP analysis on a large collection
of case and control samples will certainly help us to
delineate the underlying molecular mechanisms in the
development of different histological types of ovarian
cancer.
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